



PRIOR AUTHORIZATION REQUEST FORM

BRAND STATINS

Altoprev®, FloLipid®, Livalo®

For authorization, please answer each question and fax this form PLUS chart notes back to Real Rx at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance 385-425-5094.

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Form with fields: Date, Member Name, ID#, DOB, Gender, Physician, Office Phone, Office Fax, Office Contact.

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: [] Altoprev® (lovastatin extended-release), [] FloLipid® (simvastatin suspension), [] Livalo® (pitavastatin)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section

Table with 4 columns: Questions, Yes, No, Comments/Notes. Row 1: Is this request for an expedited review? By checking the "Yes" box to request an expedited review (24 hours), you are certifying that applying the standard review time frame (72 hours) may place the member's life, health, or ability to regain maximum function in serious jeopardy.

ALTOPREV®

Table with 4 columns: Questions, Yes, No, Comments/Notes. Rows 1-4: 1. Is the request for Altoprev®? 2. Is the request for the treatment of primary hypercholesterolemia, primary or secondary prevention of cardiovascular events, or to slow coronary atherosclerosis progression? 3. Has the member had a 90-day trial and failure or intolerance of at least 4 other generic statin therapies (e.g., simvastatin, atorvastatin, etc.)? 4. Has the member had a 90-day trial and failure of ezetimibe?

FLOLIPID®

Table with 4 columns: Questions, Yes, No, Comments/Notes. Row 1: Is the request for FloLipid®? Row 2: Is the request for treatment of primary hypercholesterolemia, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hyperlipidemia, primary or secondary

prevention of cardiovascular events, or heterozygous familial hypercholesterolemia in adolescent patients?			
3. Is the member unable to swallow or has severe dysphagia that prevents the member from taking solid oral dosage forms?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
LIVALO®			
1. Is the request for Livalo®?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Is the request for treatment of primary hypercholesterolemia or hypertriglyceridemia?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Has the member had a 90-day trial and failure or intolerance of at least 4 other high-intensity generic statin therapies (e.g., rosuvastatin, atorvastatin)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Has the member had a 90-day trial and failure of ezetimibe?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the therapy shown to be effective with an improvement in condition?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Does the member show a continued medical need for the therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician's Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM- 071
 Origination Date: 02/23/2018
 Reviewed/Revised Date: 05/17/2023
 Next Review Date: 05/17/2024
 Current Effective Date: 06/01/2023

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.